EB Research Partnership / DEBRA Translational Research
Offers translational support for pioneering research where milestones guide venture-philanthropy partnerships.
The EB Research Partnership / DEBRA Translational Research program sits under EB Research Partnership and DEBRA of America, two U.S. nonprofits working around epidermolysis bullosa, a rare inherited skin disease. The funding model is venture philanthropy: the funder places capital into promising work and can recycle returns back into new EB research. The route is active, global, and built for translational projects rather than open-ended basic science. Awards run from $50,000 to $500,000, with a median award of $200,000. The program is annual, requires for-profit teams, excludes nonprofits and individuals, and is aimed at projects around TRL 2 through 5. One-year awards can renew annually for up to five years, indirect costs are capped at 5%, and the work is expected to carry a clear commercialization plan alongside the science. The strongest fit is a team that can show a credible path to an EB therapy or enabling tool within one to four years and enough discipline to move through milestones. Drug repurposing, preclinical work, clinical work, and data-platform style tools all fit when they serve a real development path. The program is designed for teams that can combine scientific ambition with business viability and keep both moving in step.
No upcoming rounds verified. Cadence: Annual.